183500-73-4

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 183500-36-9 4-(5-hydroxymethyl-imidazol-1-ylmethyl)-benzonitrile 
• 127056-57-9 4-(tert-butyldimethylsilyloxymethyl)-1-(triphenylmethyl)imidazole 
• 17201-43-3 4-cyanobenzyl bromide 

Downstream Products

• 660855-49-2 methyl 3-[5-(t-butyl-dimethylsilanyloxymethyl)imidazol-1-yl]-3-(4-cyanophenyl)propionate 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS

Compounds of formula (I), provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employe

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras